Quantcast
Last updated on April 18, 2014 at 13:58 EDT

Latest Heather Bresch Stories

2012-02-15 06:30:00

PITTSBURGH, Feb. 15, 2012 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that it plans to change the name of its fully integrated branded specialty pharmaceutical business from Dey Pharma to Mylan Specialty. Mylan CEO Heather Bresch said: "In 2007, we united legacy Mylan, Matrix Laboratories and the generics business of Merck KGaA, which included the acquisition of our specialty subsidiary Dey Pharma, and transformed Mylan into the diversified, global business we are today. Over...

2012-02-14 16:58:00

PITTSBURGH, Feb. 14, 2012 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today commented on its response to the current shortage of preservative-free Methotrexate Injection. Mylan CEO Heather Bresch said, "We recognize the critical importance of preservative-free Methotrexate Injection in the treatment of patients with cancer, particularly the pediatric population, and share the concerns of patients and physicians about access to this important product. While Mylan has not had any manufacturing...

2012-02-10 16:17:00

PITTSBURGH, Feb. 10, 2012 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that a jury has rendered an unfavorable verdict in a patent infringement lawsuit filed by Sunovion Pharmaceuticals Inc., f/k/a Sepracor Inc., against Mylan Inc., Mylan Pharmaceuticals Inc., Dey Inc. and Dey Pharma, L.P. in relation to Dey's Abbreviated New Drug Application (ANDA) for Levalbuterol Hydrochloride (HCl) Inhalation Solution, 0.31 mg/3 mL, 0.63 mg/3 mL, 1.25 mg/3 mL and 1.25 mg/0.5mL...

2012-02-09 09:00:00

PITTSBURGH, Feb. 9, 2012 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) CEO Heather Bresch today testified before the U.S. House of Representatives Energy and Commerce Committee at a hearing hosted by the subcommittee on Health entitled "Review of the Proposed Generic Drug and Biosimilars User Fees and Further Examination of Drug Shortages." In her testimony, Bresch commented: "Every consumer should have the peace of mind in knowing that every prescription, brand or generic, dispensed in the...

2012-02-09 06:30:00

PITTSBURGH, Feb. 9, 2012 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Doxycycline Hyclate Delayed-release (DR) Tablets USP, 150 mg. This product is the generic version of Mayne Pharma's Doryx® (marketed by Warner Chilcott), which is a tetracycline-class antimicrobial. Mylan CEO...

2012-01-24 08:40:00

NEW YORK, Jan. 24, 2012 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) will host an Investor Day on Feb. 21, in New York City. Robert J. Coury, Mylan's executive chairman; Heather Bresch, chief executive officer; Rajiv Malik, president; Hal Korman, chief operating officer; John Sheehan, chief financial officer; and John Thievon, president of Dey Pharma, will present the company's financial guidance for 2012 and an overview of the company's strategic vision and growth strategy for 2013 and...

2011-12-12 06:00:00

PITTSBURGH, Dec. 12, 2011 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced the appointment of John Thievon as president of Dey Pharma, L.P., Mylan's fully integrated specialty pharmaceutical business. Thievon has more than 20 years of professional experience in strategic product launches, marketing, commercialization, sales penetration and distribution leadership. Most recently, he served as president and chief executive officer of MiddleBrook Pharmaceuticals. In this capacity, he...

2011-12-01 06:00:00

PITTSBURGH, Dec. 1, 2011 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today affirmed its commitment to expand the access of people living with HIV/AIDS in the developing world to high quality, affordable treatment. The company is the proud sponsor of a special World AIDS Day exhibition and reception today in Washington D.C. The event is hosted by the World AIDS Institute in cooperation with the Congressional HIV/AIDS Caucus. Mylan President Heather Bresch said: "As a company dedicated to meeting...

2011-11-09 11:14:00

PITTSBURGH, Nov. 9, 2011 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today applauded the Obama administration's call to action in the global fight against HIV/AIDS. Mylan President Heather Bresch commented: "While the generics industry has made significant contributions toward making HIV/AIDS medicines more affordable, we believe the focus must now turn to expanding access to treatment for more people. As such, we're heartened that the Obama administration is embracing treatment as...

2011-10-26 06:30:00

PITTSBURGH, Oct. 26, 2011 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its board of directors has approved the transition of Chairman and Chief Executive Officer Robert J. Coury into the role of executive chairman of the board, effective as of Jan. 1, 2012. At that time, Mylan President Heather Bresch will become chief executive officer, reporting directly to the board of directors, and Chief Operating Officer Rajiv Malik will be promoted to the role of president....